Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As we have seen this stock made a surprise spike to 7 dollars since my last alert on 12/21. Keep it on your radar.
The progress this company has made is phenomenal, this is the time to jump in. This stock will not remain under a dollar for long. Start accumulating.
Hello everyone. Just got back on IHUB after being gone for a long while. Hope everyone is doing fantastic. Happy holidays everyone.
So I came across this stock and from what I read, it seems very promising.
How is everyone feeling about it so far?
Seems quiet here. Keeps eyes on AHI. Good solid news around the corner.
This stock is a must have in your portfolio. The company has taken the necessary steps to get on the right track for growth. The good news is they are already operating in so many countries. They just ran into some bumps in the road and now it all behind them. Imho this is a 10 dollars plus stock.
Where did you see that? also don't you think he is going to use the money to build the next ship?
what's going on with the world of FNMA? It has been a while friends. Hope everyone is doing well.
$Assertio Holdings Inc This is a very smart move by the company, here is why and what it does. In short, buy the friking dip.
These transactions?? reduce our overall debt by $30M, or 42.9%, while consuming only $10.5M in cash (and issue ~$7M shares). In addition, the transactions will ??save the company $2M in annual interest payments, reduce the potential dilution from the exchanged convertible notes by 4.6%, and will be accretive to our diluted EPS by $0.02 in 2023," CEO Dan Peisert commented.
??????????????????????????????
This week should be great for BNGO. Accumulate before it crosses the $10 mark.
This company has made a huge turn around, this stock will be over a dollar in the near future. Time to accumulate, add and hold.
Stay strong, do not sell.
Just a quick post to say to anyone that thinks IBIO is going to drop down, think again. This is normal rise and lots of profit taking. But the facts we know supersedes any fake or negative news about the company.
I Stated my prediction on another board that within a week to 10 days we should see a solid rise. ??
Glta.
Atom, I always encourage investors to have a plan and you my friend have a solid plan.
I have read some of your posts. You are genuine and post facts. Well done.
Keep up the goos work.
Brother Brooge, I am so sorry for your loss, never easy to lose a parent.
Rest assured she is in a better place than this crazy planet of ours.
They really had meaning to life, technology consumes us, we are no longer humans, we are walking zombies. Its only going to get worse for us.
Best of luck to you! Mom is watching over you!
Go FNMA.
Understanding this is the key to understanding why WP1122 may represent a major breakthrough. Glycolysis and glycosylation sound similar, but they are very different, even though they rely on the same base material, glucose, which is essentially sugar. In highly simplified terms, glycolysis converts glucose into fuel and glycosylation uses glucose to help build important protein structures that enable the way our cells function with each other and respond to changes in their environment. When viruses like SARS-CoV-2 invade our cells, they coopt these processes to increase both their infectivity and their replication.
The Slightly Longer Version
Moleculin has a unique opportunity to contribute to the global challenge posed by coronavirus and other viruses threatening our communities. We recently announced a collaboration with a major Texas university institution to evaluate our drug candidate, WP1122, and its analogs and this has now been followed by collaborations with additional players who bring the needed expertise to fully develop this new potential treatment for diseases like COVID-19.
Independent researchers at the Institute of Biochemistry II – Goethe-Universität Frankfurt in Germany recently announced their discovery that 2-DG, the active compound in WP1122, reduced in vitro replication of SARS-CoV-2 by 100%.
We now have a very strong reason to believe that WP1122 may be effective against COVID-19. This is based on the vital roles that glucose plays in the proliferation of SARS-CoV-2. Viruses like SARS-CoV-2 place increased demand on glucose and upregulate their host cell’s metabolic processes. Some of the most important of these processes are believed to be glycolysis and glycosylation.
Tackling Coronavirus with WP1122
The Short Version
Viruses (like SARS-CoV-2) depend on glycolysis and glycosylation for infectivity and replication.
Glycolysis and glycosylation can be disrupted by using a glucose decoy known as 2-DG.
And, while 2-DG has been shown to be effective in vitro, 2-DG’s lack of drug-like properties makes it ineffective as a drug in humans.
WP1122 has the potential to solve 2-DG’s problem by creating a prodrug of 2-DG that reaches much higher tissue/organ concentrations than 2-DG alone.
We are moving as quickly as possible to prepare WP1122 for clinical evaluation in the treatment of COVID-19.
Straight from the horses mouth.
Tackling COVID-19 with WP1122
We have a unique opportunity to contribute to the global challenge posed by coronavirus and other viruses threatening our communities. The active compound in WP1122 was found to reduce in vitro replication of SARS-CoV-2 by 100%.
How is everyone feeling about MBRX? From what I know, the company is doing very well with progress, development and seeking approval.
I have a feeling something good or should I say very good is brewing and this is what we are reading all the recent news and moves the company is doing.
I believe the WP1122 is going to kick butt and is going to stop covid in its track 100%. The key is to stop the replication and so far the science in the lab proved that, I am sure since then a lot of progress has bee taking place behind the scene.
Let's keep each other posted and updated. its a win for all.
Negative energy has no place in my book, so to all the negative people, don't waste your time replying garbage.
How is everyone feeling about ASRT?.
Cheers.
Brooge, just saw your message, have not been on here much. Will try to be in the near future.
It has been hard. loosing a mother is the worst thing. The sad part since she is 800 miles away I was not able to travel and go see her and attend her funeral. I think this is the reason I still get the urge to call her, then my brain wakes up and realizes that she is gone and I can no longer hear her voice.
Please friends, if your parents are still alive, no matter how good or bad the relationship is, call them, thank them for all they did for you when you were growing up and remind them how much you appreciate them and how much you love them.
I am a father and when my girls randomly tell me they love me, its like winning the universe, not just the lottery.
Thank you for your kind words Brooge.
Why Fannie Mae and Freddie Mac Privatizations Are Still On Track.
October is around the corner, I am sure we can wait a bit longer, we have waited 10 years...we can wait a few more month.
Last week, the U.S. Supreme Court agreed to review an investors' suit against the U.S. Treasury Department related to the bailout and later conservatorships of Fannie Mae (FNMA) and Freddie Mac (FMCC) following the financial crisis of 2008. The case is scheduled for review during the court term beginning in October.
As we noted last week, the main issue is whether the investors are entitled to a share in the $300 billion or so that the two agencies' conservator, the Federal Housing Finance Agency (FHFA), have forced Fannie and Freddie to turn over to the U.S. Treasury since 2013.
Among the other major issues facing Fannie and Freddie is the timetable for recapitalizing these two government-sponsored enterprises (GSEs). On the current timetable, a follow-on offering of shares in the two agencies would take place in July of next year. If the offering were to be compared to an IPO, it may be the largest ever, if the GSEs end up seeking an expected $200 billion in fresh cash.
Analysts at Nomura/Instinet have issued new research on the second-quarter earnings of Fannie and Freddie that are substantially higher than the firm's prior estimates. Instinet raised its core earnings per share (EPS) estimate for Fannie Mae from $0.19 to $0.41 and its EPS estimate for Freddie Mac from $0.16 to $0.38.
The basis for the higher estimates is expected strong top-line results combined with lower credit costs. Instinet calculates the potential upside on Fannie Mae stock at just over 125% from a closing price Thursday of $2.22 and a price target of $5.00. The firm rates the shares a Buy.
Freddie Mac's potential upside is 124%, based on a closing price Thursday of $2.23 and a price target of $5.00. Like Fannie, Freddie is rated as a Buy.
Instinet analyst Matthew Howlett notes that not included in the EPS estimates are realized/unrealized pretax gains of $155 million and $1.2 billion for Fannie and Freddie, respectively, compared to losses of $434 million and $835 million, respectively, in the first quarter.
Howlett made no changes to Instinet's estimated timeline for a recapitalization of the GSEs. The firm expects a final capital rule by the fourth quarter of this year, along with an exit from the FHFA's conservatorship of both agencies. An amended preferred stock purchase agreement (PSPA) continues to be expected in the fourth quarter of 2020 or the first quarter of 2021.
Interestingly, Instinet modeled a scenario in which Fannie and Freddie separately negotiate settlements and exchange offers rather than waiting for a PSPA from Treasury. The model calculated "no change to our valuation analysis if Fannie's [or Freddie's] junior preferreds are left outstanding and common stock dividends are delayed by one year."
Howlett commented that in Instinet's view, "the biggest obstacle to [recapitalization and release from conservatorship] isn't political, it's [economic]."
That may be true, but unless Congress agrees explicitly to backstop Fannie's and Freddie's guarantees, the economics of the GSEs' recapitalization may take a back seat to the political concerns. While the two agencies have always enjoyed an implicit federal backstop, that may not be enough to raise as much cash as Fannie and Freddie would need under an FHFA capital rule.
Things for investors to watch for, according to Instinet, include near-term announcements related to relisting of the GSEs' public securities, a search for legal counsel to coincide with settlement discussion among litigating shareholders, and a timeline for public comment on whatever FHFA proposes as the GSEs capital rule.
Instinet expects Fannie's net revenue in 2020 to total $23 billion, rising to $24 billion in 2021. Cash and equivalents, which totaled $21 billion in 2019, are expected to increase to $82 billion this year and to $83 billion in 2021. Diluted shares outstanding are expected to rise from 5.76 billion this year to 18.02 billion in 2021, and GAAP EPS is forecast at $1.48 in 2020 and $1.28 in 2021.
Freddie Mac is forecast to post net revenue this year of $14 billion, rising to $15 billion next year. Cash and equivalents of $5 billion rise to $6 billion in 2021. Diluted shares outstanding total 3.23 billion this year and are expected to rise to 12.02 billion in 2021. GAAP EPS are forecast at $1.54 this year and $1.25 next year.
I know they were talking about a 30 million contract, hope to hear about that in the near future.
action8101, haha, made me laugh...I have been around, just busy and when I realized not much was going to take place with FNMA, I focused on what's important.
Nice to hear from you.
Take care and be safe.
Mike, my friend...bless you heart...I am around, just been going through a lot. But hopefully things get better, for all of us. This Covid is a wake up call for all of us.
I say no matter what this is (talking about covid)...if its man made, or nature decided to mess with us, i hope it brings the best out of us. We need to be kind and patient with each other. We truly take noting to grave with us.
There is a huge change taking place in our lives and I hope we embrace it, learn from it, grow and become better people.
GO FNMA
Good to hear from you! Glad you are still around.
Hi Josephs, I am ok, Immediate family is ok...Lost 3 people dear to me in the last 30 days. One of them was my mom. It has been rough.
Investing has been rewarding.
Some that I am on now are IBIO, AYTU, MBRX, ASRT. Had VXRT, sold it too early before it shot from the low 1's and 2's all the way to 16 dollars. Missed a huge opportunity.
Glad, all is well with you, stay strong.
Go FNMA
10bambam, Nice to hear from you, I am so sorry to hear about your unfortunate health situation. I, along with everyone on here are glad you are doing well and back on your feet again.
Yes, I can say the same thing with regards being busy away from the board and noticed that nothing changed, lots of false promises by the current administration. (unless I missed something, I take this back).
IMHO - Eventually they will be freed. Even a murder gets freed from jail...haha. FNMA is not guilty, FNMA will be free soon.
Once again, I am so glad you are well. May you have a blessed and healthy life from this moment on.
GLTY & All.
How is the FNMA Family doing, who is still here from a year ago. Miss my old buddies on here. Say hello if you are still following FNMA,
Cheers,
Crawford.
Breaking News - AcelRx Wins ~$3.5M US Army Medical Research Acquisition Contract For Dsuvia
5:33pm ET 7/16/2020 Benzinga
The United Stated Army Medical Research Acquisition Activity (USAMRAA), in support of the U.S. Army Medical Materiel Development Activity (USAMMDA), intends to negotiate solely (as prescribed in FAR 13.106(b)(1)(i)) with AcelRx Pharmaceuticals, Inc., 351 Galveston Drive, Redwood City, CA, 94063-4736, as the only responsible source that can provide one (1) commercial lot of 3,200 boxes of U.S. Food and Drug Administration (FDA) approved Sufentanil NanoTab brand name Dsuvia (New Drug Application (NDA)) # 209128 letter dated 12 December 2016. Dsuvia is for the management of acute pain in adults in medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments. Dsuvia is supplied in a 30 microgram tablet in a single-dose, prefilled applicator for administration by a healthcare professional, and it will not be available in retail pharmacies or for outpatient use. This acquisition is being conducted under FAR Part 12 Acquisition of Commercial Items. Provisions and clauses in effect through Federal Acquisition Circular (FAC) 2020-04, dated 15 January 2020, are incorporated.
USAMMDA, located in Fort Detrick, MD, is a subordinate activity under U.S. Army Medical Research and Development Command (USAMRDC) supporting the Command as the primary advanced development medical research, development, and acquisition organization within DOD and is responsible for meeting medical developmental requirements from both the Army and other military services. The USAMMDA is the Department of Defense's (DOD) medical product development activity for products designed to protect and preserve the lives of Warfighters. The USAMMDA develops new drugs, vaccines, devices, and medical support equipment that enhance readiness, ensures the provision of the highest quality medical care to the DOD, and maximizes survival of medical casualties on the battlefield. USAMMDA project managers guide the development of medical products for the U.S. Army Medical Department, other U.S. Services, the Joint Staff, the Defense Health Agency, and U.S. Special Forces community. The process takes promising technology from DOD, industry, and academia to U.S. Forces, from the testing required for FDA approval or licensing, to fielding and sustainment of the finished product.
USAMMDA’s, Warfighter Protection and Acute Care (WPAC) Project Management Office intends to procure firm-fixed-price contract for FDA approved brand name Dsuvia to be used to conduct a comparative clinical trial to aid clinical practice guideline development. USAMMDA has a requirement for one commercial lot of 3,200 boxes of FDA approved brand name Dsuvia, with a base and three (3) optional Contract Line Item Numbers (CLINs) to procure up to 3,000 boxes per CLIN of FDA brand name Dsuvia. The goal of the clinical trial is gain information regarding acceptability of Dsuvia compared to Oral Transmucosal Fentanyl Citrate (OTFC) in an Emergency Room (ER) setting in patients with moderate to severe pain requiring an opioid. The clinical trial contains several secondary endpoints including healthcare provider feedback. Based on the above information, the only technically acceptable product is provided by AcelRx Pharmaceuticals, Inc. The maximum estimated dollar amount for the duration of the contract is $3,525,800.00.
The intended procurement will be classified under North American Industry Classification System (NAICS) 325412 Pharmaceutical Preparation Manufacturing with a Small Business Size Standard of 1250 employees. This notice of intent is not a request for competitive proposals and no solicitation document will be posted for this requirement. However, parties interested in responding to this notice shall submit technical data, including cost, sufficient to determine capability in providing the same product. All capability statements received by closing of this notification of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.
$AYTU, What we have been seeing lately is large size accumulation of AYTU share. In addition, the leadership have been working hard behind the scene and they seem to keep a sealed lip on the development of healight. It has been three month since we heard any update on healight which tells me for someone to release hint it to prepare shareholders and investors to load up so they can help raise money to develop the devices so they are able to cater to the covid-19 patients that are in critical condition.
Let's keep ears to the ground and share what we find out so we can make an informed decision.
glta.
Something definitely going on, large buys after hours. I am hoping it breaks like VXRT - Owned 25,000 at $1.25. Sold by mistake at $3.00.
Put a sale order as a teaser, forgot about it...it sold my shares. ughhh.
Won't make this mistake with IBIO.
IMHO - One news of a large contract and this stock will go over $10.00.
GLTA>
I would recommend reaching out here and asking questions:
Investor Contact Information
Investor Relations
Lytham Partners, LLC
Joe Dorame
Managing Partner
T: (602) 889-9700
Auditor
Grant Thornton LLP
www.grantthornton.com
Transfer Agent
VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
www.VStockTransfer.com
Legal Counsel
Schiff Hardin LLP
www.schiffhardin.com
Thank you for sharing. IMHO, this test will be stopped in no time. It is too dangerous. Why? Because the chances of the person doing the test on them self getting the package contaminated is very high. Too dangerous for the mailman, post office workes, and cross contamination with other mailers, plus the staff at the lab may get infected.
I don't see this is a good option, this test must be done at the Dr's office under preffessional trained staff.
Some valuable information to know.
Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturers, and Food and Drug Administration Staff Document issued on the web on March 16, 2020.
This document supersedes “Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing under Clinical Laboratory Improvement Amendments (CLIA) prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency” issued February 29, 2020.
For questions about this document, contact CDRH-EUA-Templates@fda.hhs.gov.
U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health
https://aytu-ugrgkocy.stackpathdns.com/wp-content/uploads/2020/03/IIE-COVID19-Guidance.pdf
COVID-19 IgG/IgM Point of Care Rapid Test
The COVID-19 IgG/IgM Rapid Test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 novel coronavirus in human whole blood, serum or plasma. The company’s licensed COVID-19 IgG/IgM Rapid Test is authorized for distribution throughout the U.S. based upon the FDA’s Emergency Use Authorization (EUA) policy. The COVID-19 IgG/IgM Rapid Test is intended for professional use only and delivers clinical results between 2 and 10 minutes at the point-of-care by analyzing samples from individuals having signs and symptoms of SARS-CoV-2 infection.
This test has been validated in a 126 patient clinical trial and is CE marked.
DISCLAIMER: Aytu BioScience has notified the FDA that we have validated and will begin offering the COVID-19 IgG/IgM Rapid Test. The test is being made available under compliance with Section IV.D. of the FDA’s Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency. Updated FDA guidance, issued on March 16, 2020, allows the distribution of this product for diagnostic use in laboratories or by healthcare workers at the point-of-care. The updated policy can be viewed by clicking here. The FDA has not reviewed Aytu BioScience’s validation of the test.
Dragon Lady, very well stated. Excellent news on todays call.
IMHO this stock will not be under $2.00 for long.
Thank you for all your support on here by being informative.
Dragon lady, Thank you for taking the time to share this valuable information I am sure many on this board appreciate you!
Good luck wish great success in your trades
S.C
Aytu BioScience Announces Publication of Results from Natesto Spermatogenesis Study in Journal of Urology
8:01 am ET April 21, 2020 (Accesswire) Print
Nasally-Administered Natesto Testosterone Replacement Therapy Increases Serum Testosterone, Improves Hypogonadal Symptoms While Simultaneously Preserving Semen Parameters and Gonadotropin Hormones
ENGLEWOOD, CO / ACCESSWIRE / April 21, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced the acceptance and publication of the Natesto® Spermatogenesis Study results into the Journal of Urology earlier this week.
The Phase IV single institution, prospective, clinical trial was conducted between November 2017 and September 2019 at the University of Miami's Department of Urology by lead author and the study's principal investigator Dr. Ranjith Ramasamy, MD, the Director of Reproductive Urology. The study concluded that Natesto was effective in returning hypogonadal men to back to normal testosterone levels, significantly improve erectile function and quality of life, preserve gonadotropin hormones, and most importantly preserve semen parameters through 6 months of treatment.
Studies estimate ~12.4 - 15.6% of men under 39 years old receive prescribed testosterone therapy (TTh). The most commonly prescribed testosterone therapies, injections and topical gels, can impair semen parameters and can cause azoospermia in up to 65% of men. Additionally, off-label use of therapies such as selective estrogen receptor modulators (SERMs) are widely used to preserve spermatogenesis while simultaneously increasing testosterone. Many of these off-label products can have numerous additional adverse reactions, therefore identifying alternatives to increase testosterone in men without impacting fertility is paramount.
The authors note, Natesto differs substantially in its short duration of action and frequency of administration, compared to other long-acting testosterone injections, gels, and pellets. They hypothesized that short-acting Natesto would have less suppressive effects on the hypothalamic-pituitary-gonadal (HPG) axis, and therefore lead to less suppression of spermatogenesis.
"The results from this clinical trial are encouraging - Natesto can be a safe and effective treatment option for men who wish to preserve fertility and sperm production," said the study's principal investigator Dr. Ranjith Ramasamy, Associate Professor and Director of Reproductive Urology at the University of Miami School of Medicine.
The Phase IV clinical trial investigating the impact of nasally-administered Natesto on preservation of fertility parameters evaluated 44 subjects through 3 months, and 33 subjects through 6 months of treatment. Mean testosterone increased from 231 ng/dL to 652 ng/dL after 6 months of Natesto treatment. There was improvement across all domains of erectile function (based in IIEF-15), with particularly significant improvements in sexual desire and overall satisfaction. Additionally, sperm concentration, sperm motility, and total motile sperm count were maintained through 6 months of Natesto treatment.
Mean Values (SD)
Baseline
3 Months
6 months
P value
Testosterone (ng / dL)
231 (61)
616 (267)
652 (305)
< 0.001
Semen Parameters
Sperm Concentration (Mill. / cc)
29.9 (18.7)
25.9 (19.5)
24.2 (15.7)
> 0.05
Sperm Motility (%)
52.1 (12.3)
49.1 (20.4)
51.6 (15.2)
> 0.05
Total Motile Sperm Count (Mill.)
45.9 (45.5)
40.8 (60.5)
33.9 (24.3)
> 0.05
Symptom Improvement
IIEF - Sexual Desire
5.8 (2.2)
7.6 (1.3)
7.3 (1.6)
< 0.001
IIEF - Overall Satisfaction
6.0 (2.8)
7.8 (2.0)
7.8 (2.1)
0.001
Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "The investigators, led by Dr. Ramasamy, clearly conclude from this study that hypogonadal men treated with Natesto are able to maintain their fertility as evidenced by the study participants' maintenance of key semen parameters.
For the first time, a testosterone replacement therapy has been shown to increase serum testosterone while actually maintaining sperm concentration, motility, and total motile sperm count. This distinguishes Natesto from all other testosterone replacement therapies and can create a clinical paradigm shift across the spectrum of male reproductive health. With these data now published, we believe Natesto will be primed for broader use and may present a more appropriate treatment for men with Low T who are still in their family formation years."
Aytu BioScience's Natesto co-promotion partner Acerus will evaluate options with respect to Natesto product labeling claims as it relates specifically to these study results and data.
Very Powerful Message:“This is the breakthrough we were looking for"
“This is the breakthrough we were looking for, only it came from an unexpected source,” commented Walter Klemp, CEO of Moleculin. “Normally, we wouldn’t have access to data like this until it is published, but the willingness of the authors to pre-release this data will help support our development of WP1122 for treating COVID-19.”
Moleculin’s Chief Medical Officer, Dr. Sandra Silberman added: “The FDA has cleared the way for very rapid development of COVID-19 therapies, so we should be able to move WP1122 into the clinics on an expedited basis.”
She also revealed that the drug has a very good safety profile in mice, and is now being tested on additional species before the company submits its IND (Investigational New Drug application).
Only two analysts have published recent ratings on MBRX- and both rate the stock a buy. Based on the outlook for Moleculin’s next generation anthracycline Annamycin, Oppenheimer’s Kevin DeGeeter published a buy rating with a $2 price target on April 2. That indicates further upside potential of 255%.
So let's recap todays news.
Overall good news came out, we have one in Feb( Regarding Cancer and today Regarding Covid-19).
So over all the company is doing well and moving in the right direction.
IMHO - Now that the news is out and there is desperate need for their covid-19 treatment (2-deoxy-D-glucose (2-DG) totally stopped the replication of the SARS-CoV-2 virus.)
This is not something to play around with or falsely announce, the SEC will Chew them up and law suits will be all over. The good news is - this is not the case here.
It's fun to look at chat boards and read the message cheerleaders write and those that bash them...but at the end of the day slid traders trade with a plan and a strategy. Ok it went up and down so what. Have you ever seen any one stock keep going and going and going. (I did - the Duracell bunny - He keeps going and going and going) - Smile. Making a joke here.
So as times have changed from when our parents use to trade to now where traders are younger and they are happy with a $100 profit in a day.
So, trade with a confidence, have a plan, and entry point and an exit point. Ignore the noise. As we all know without a shadow if a doubt, there is something called :Shorting Stocks". So you are going to see those that are going to influence your decision and cause you to trade against your original plan. Ok Enough Said.
Let's have an awesome day tomorrow.
My Views based on what we know, we see a bit of manipulation and then we go up. With all the positive news, it would be crazy to sell your shares, especially if you bought them close to the $0.60 range.
Nano cap Moleculin Biotech (NASDAQ:MBRX) announces the results of in vitro testing in Germany showing that 2-deoxy-D-glucose (2-DG) totally stopped the replication of the SARS-CoV-2 virus. Specifically, researchers at the University of Frankfurt reported that inhibiting glycolysis (sugar metabolism) with non-toxic concentrations of 2-DG prevented the coronavirus from replicating in cell culture. 2-DG inhibits glycolysis because it is a decoy that cannot be converted into energy.
The company's WP112 candidate is a prodrug of 2-DG (a prodrug is an inactive compound that is metabolized in the body to produce the active drug) that, it says, may have therapeutic potential in COVID-19 since 2-DG in its normal state is metabolized too quickly to be effective. WP112 is only metabolized once it is inside the cell, enabling much higher tissue and organ concentrations of 2-DG.
An IND filing, clearing the way for clinical studies, is next up.
Shares up 115% premarket on robust volume.
Aytu BioScience Begins Shipping Coronavirus Serology Tests
1:13 pm ET April 3, 2020 (Dow Jones) Print
By Josh Beckerman
Aytu BioScience Inc. said it began shipping its coronavirus disease Covid-19 IgG/IgM rapid test to U.S. customers.
The company has received orders for the serology tests from large medical centers, municipalities, first responders and other customers.
Aytu said the Denver Police Department purchased the company's first 2,750 rapid tests.
Aytu shares recently traded at $1.56, down 1 cent.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
April 03, 2020 13:13 ET (17:13 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.